Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.
Perttu LahtinenJalanka JonnaAnna HartikainenEero MattilaMarkku HilliläJari PunkkinenJari KoskenpatoVeli-Jukka AnttilaJyrki TillonenSatokari ReettaPerttu ArkkilaPublished in: Alimentary pharmacology & therapeutics (2020)
FMT provided only a transient relief of symptoms, although it induced a sustained alteration in the microbiota of IBS patients. Therefore, FMT delivered by a single infusion via colonoscopy cannot be recommended as a treatment for IBS in clinical practice. ClinicalTrials.Org, Trial registration number: NCT03561519.
Keyphrases
- irritable bowel syndrome
- clinical trial
- phase iii
- study protocol
- double blind
- clinical practice
- end stage renal disease
- open label
- phase ii
- ejection fraction
- chronic kidney disease
- newly diagnosed
- cell therapy
- prognostic factors
- high glucose
- stem cells
- patient reported outcomes
- diabetic rats
- platelet rich plasma
- oxidative stress
- cerebral ischemia
- combination therapy
- blood brain barrier
- replacement therapy